BNP Paribas Funds Health Care Innovators Classic CapitalisationRegister to Unlock Ratings |
Performance History | 29/02/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 15.7 | 11.5 | 6.8 | -2.0 | 6.3 | |
+/-Cat | -1.8 | 2.0 | 11.5 | 1.1 | 2.8 | |
+/-B’mrk | - | -6.8 | 1.0 | 0.5 | 0.8 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 27/03/2024 | EUR 1697.21 | |
Day Change | 1.04% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0823416762 | |
Fund Size (Mil) 27/03/2024 | EUR 1643.36 | |
Share Class Size (Mil) 27/03/2024 | EUR 1183.75 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 01/05/2023 | 1.98% |
Investment Objective: BNP Paribas Funds Health Care Innovators Classic Capitalisation |
Increase the value of its assets over the medium term by investing in healthcare innovative companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Jon Stephenson 02/05/2016 | ||
Christian Fay 09/07/2018 | ||
Inception Date 17/05/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care 10/40 NR EUR | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BNP Paribas Funds Health Care Innovators Classic Capitalisation | 31/01/2024 |
|
|
Top 5 Holdings | Sector | % |
UnitedHealth Group Inc | Healthcare | 7.87 |
Eli Lilly and Co | Healthcare | 7.15 |
AstraZeneca PLC | Healthcare | 6.48 |
Boston Scientific Corp | Healthcare | 5.13 |
Sanofi SA | Healthcare | 5.10 |
Increase Decrease New since last portfolio | ||
BNP Paribas Funds Health Care Innovators Classic Capitalisation |